TherOx Inc.02.24.16
TherOx Inc. a privately held medical device company focused on improved treatment of Acute Myocardial Infarction (AMI), has announced the appointment of D. Keith Grossman to its board of directors.
“Keith is a recognized leader in our industry, and brings a wealth of experience and judgment in guiding innovative device companies through aggressive growth, strategic change, and value creation. I’m confident he will make vital contributions to TherOx as we continue to advance toward our goal of bringing SuperSaturated Oxygen Therapy to the U.S. market,” said Kevin T. Larkin, president/CEO of TherOx.
SuperSaturated Oxygen (SSO2)Therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients and thus reduce infarct size.
Grossman has more than 30 years of experience in the medical device field. Grossman served most recently, and for the second time, as president, CEO and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical Inc. Prior to Thoratec, he served as president, CEO and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Grossman served as Thoratec’s president, CEO and director for the first 10 years of its growth as a commercial company.
Grossman currently serves as a member of the board of directors of ZELTIQ Aesthetics Inc. and as chairman of Outset Medical Inc. (privately held) and previously served as a board member for Intuitive Surgical Inc., Kyphon, Inc., and a number of privately held medical device companies.
Grossman received a Bachelor of Science degree in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.
TherOx is a privately held medical device company based in Irvine, Calif., focused on developing and commercializing SuperSaturated Oxygen (SSO2) Therapy for the AMI patient population. According to the American Heart Association, every year nearly 1 million people in the United States have heart attacks.
“Keith is a recognized leader in our industry, and brings a wealth of experience and judgment in guiding innovative device companies through aggressive growth, strategic change, and value creation. I’m confident he will make vital contributions to TherOx as we continue to advance toward our goal of bringing SuperSaturated Oxygen Therapy to the U.S. market,” said Kevin T. Larkin, president/CEO of TherOx.
SuperSaturated Oxygen (SSO2)Therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients and thus reduce infarct size.
Grossman has more than 30 years of experience in the medical device field. Grossman served most recently, and for the second time, as president, CEO and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical Inc. Prior to Thoratec, he served as president, CEO and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Grossman served as Thoratec’s president, CEO and director for the first 10 years of its growth as a commercial company.
Grossman currently serves as a member of the board of directors of ZELTIQ Aesthetics Inc. and as chairman of Outset Medical Inc. (privately held) and previously served as a board member for Intuitive Surgical Inc., Kyphon, Inc., and a number of privately held medical device companies.
Grossman received a Bachelor of Science degree in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.
TherOx is a privately held medical device company based in Irvine, Calif., focused on developing and commercializing SuperSaturated Oxygen (SSO2) Therapy for the AMI patient population. According to the American Heart Association, every year nearly 1 million people in the United States have heart attacks.